Oppenheimer analyst Jay Olson maintained a Buy rating on Madrigal Pharmaceuticals (MDGL) today and set a price target of $200.00. The company’s shares closed last Wednesday at $73.78.
According to TipRanks.com, Olson has currently no stars on a ranking scale of 0-5 stars, with an average return of -13.0% and a 32.4% success rate. Olson covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Enanta Pharmaceuticals, and Axovant Gene Therapies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Madrigal Pharmaceuticals with a $180.40 average price target, a 150.5% upside from current levels. In a report released today, B.Riley FBR also reiterated a Buy rating on the stock with a $134.00 price target.
See today’s analyst top recommended stocks >>
Based on Madrigal Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $27.74 million. In comparison, last year the company had a GAAP net loss of $11.48 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
